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Universal thyroid screening in pregnancy is a key debate in thyroidology and obstetrics.
It is well-established that thyroid hormones are essential for maintaining pregnancy and
optimal fetal development. Thyroid dysfunction is common in women of child-bearing
age and also results in substantial adverse obstetric and child neurodevelopmental
outcomes. Furthermore, thyroid dysfunction is readily diagnosed with reliable blood
tests and easily corrected with inexpensive and available treatments. Screening only
high-risk patients appears to miss the majority of cases and economic models show
that compared to high-risk screening, universal screening is cost effective even if
only overt hypothyroidism was assumed to have adverse obstetric effects. As a
result, several countries now implement universal screening. Opponents of universal
thyroid screening argue that asymptomatic borderline thyroid abnormalities such as
subclinical hypothyroidism and isolated hypothyroxinemia form the bulk of cases of
thyroid dysfunction seen in pregnancy and that there is a lack of high quality evidence
to support their screening and correction. This review critically appraises the literature,
examines the pros and cons of universal thyroid screening using criteria laid down by
Wilson and Jungner. It also highlights the growing evidence for universal thyroid screening
and indicates the key challenges and practicalities of implementation.
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INTRODUCTION
Thyroid hormones are essential for maintaining pregnancy and optimal fetal development (1, 2).
It is well-established that overt thyroid disease is associated with adverse obstetric and offspring
neuro-developmental outcomes (1, 3). More recently there has been growing concern that more
marginal degrees of thyroid dysfunction particularly subclinical hypothyroidism (elevated TSH and
normal FT4 concentration) and isolated hypothyroxinemia (normal TSH and low FT4) are also
associated with fetal loss, prematurity and impaired offspring cognitive function (4–6). In some
studies, maternal thyroid autoimmunity has also been identified as a potential risk for fetal loss (1).
Because thyroid disorders are particularly common in women of reproductive age, thyroid
dysfunction is frequently encountered during pregnancy, sometimes as a new diagnosis (7, 8). The
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prevalence of hypothyroidism is about 2% in iodine sufficient
areas while overt and subclinical thyrotoxicosis occur in ∼0.2
and 2.5% of pregnancies, respectively (9). Such thyroid disorders
are frequently asymptomatic or difficult to distinguish from the
features of normal pregnancy on clinical grounds alone. Thus, it
would seem logical to systematically screen pregnant woman for
thyroid disorders. However, such a screening strategy is likely to
predominantly identify women with subclinical thyroid disease
for whom the benefits of systematic screening and correction
remain controversial (10, 11).
These competing considerations have fuelled continued
debate on the merits of gestational thyroid screening (12). While
universal thyroid screening is recommended in countries such
as Spain (13), China (14), and Poland (15), other countries
including the United Kingdom and the United States adopt
a case-finding approach targeted at women at high-risk of
thyroid dysfunction (16). In 1968, James Wilson and Gunner
Jungner published their classic report on the principles and
practice of screening in which they set down a number
of pertinent criteria that should be considered before a
screening programme is adopted (Box 1) (17). These criteria
have since been widely applied to screening decisions and
have stood the test of time as a gold standard tool for
screening policies. In this review, we appraise the potential
benefits and drawbacks of universal thyroid screening in
early pregnancy using the Wilson and Jungner criteria (17)
(Box 1).
CRITERIA 1: IS THE CONDITION AN
IMPORTANT HEALTH PROBLEM?
Pros
It is well-established that overt thyroid dysfunction is an
important health condition in pregnancy. Overt hypothyroidism
occurs in ∼0.2–0.6% of pregnant women (2, 18) while overt
hyperthyroidism, usually due to Graves’ disease, occurs with
a frequency of about 0.2% (3). More modest abnormalities of
thyroid function are more prevalent. Subclinical hypothyroidism
occurs in 2–3% of pregnancies (1, 16) and the prevalence of
isolated hypothyroxinemia, defined as a normal TSH with FT4
Box 1 | Screening criteria.
1. Is the condition an important health problem?
2. Is there an accepted treatment?
3. Are facilities for diagnosis and treatment readily available?
4. Is there a recognizable latent or early symptomatic stage?
5. Is there a suitable test or examination?
6. Is the test acceptable to the population?
7. Is the natural history of the condition, adequately understood?
8. Is there an agreed policy on whom to treat?
9. Is the cost of case-finding economically viable?
10. Case-finding should be a continuing process and not a “once and for all”
project.
Adapted from Wilson and Jungner (17).
below the 2.5 percentiles occurs in around 2% of pregnancies
(19). In early gestation, fetal reliance on maternal thyroxine
delivery coincides with a period of critical developmental
landmarks such as neuronal proliferation, migration, and neural
tube formation (20). Thus, maternal thyroid dysfunction in
early pregnancy may have permanent repercussions on child
neurodevelopment as exemplified in the devastating neurological
sequelae of uncorrected congenital hypothyroidism or severe
iodine deficiency (21).
In addition, observational studies show that offspring of
women with hypothyroidism (22) or isolated hypothyroxinaemia
(23), suffer with ∼2–7-point deficits in IQ compared to children
of euthyroid mothers (24). Two RCTs, the Controlled Antenatal
Thyroid Screening (CATS) study (10), and a United States
National Institutes of Health study by Casey et al. (11),
have investigated the impact of systematic screening and
correction of maternal subclinical thyroid dysfunction on child
intellectual function. These studies showed no benefits of
maternal levothyroxine on child IQ when evaluated at age 3 years
(10) and 9 years (25) in the CATS study, and at 3–5 years in the
study by Casey et al. (11). In both studies however, levothyroxine
was initiated at a median gestational age of 13–18 weeks which
would have been after the critical neurodevelopmental period
and therefore possibly too late to have had an impact on fetal
brain development.
Women with thyroid dysfunction also suffer an increased
risk of adverse pregnancy outcomes an association which
is well-established for overt thyroid dysfunction but is also
seen with subclinical hypothyroidism (26). One meta-analysis
showed significant risks of miscarriages (odds ratio 1.93,
95% confidence interval 1.4, 2.64) and pre-term loss (odds
ratio 1.3, 95% confidence interval 1.05, 6.0) in women with
subclinical hypothyroidism (6). Two small fertility clinic trials
in women undergoing assisted reproduction techniques also
reported beneficial effects of levothyroxine in increasing clinical
pregnancy and live birth rates in women with subclinical
hypothyroidism (27, 28). In a prospective controlled trial,
systematic screening and correction of gestational subclinical
hypothyroidism significantly reduced adverse pregnancy events
in the sub-group of women classified as low risk for thyroid
disease (29).
Cons
The health impact of overt thyroid dysfunction is not
in doubt but the bulk of cases of thyroid dysfunction
that will be detected by systematic screening in pregnancy
will be asymptomatic subclinical or borderline biochemical
abnormalities. For example, subclinical hyperthyroidism, in
which TSH is low in the presence of normal FT4, is usually
due to the transient thyroid stimulatory effects of human
chorionic gonadotrophin (hCG) and does not require treatment
(30). Also, the significance of subclinical hypothyroidism or
isolated hypothyroxinaemia and the benefits of correcting these
biochemical abnormalities has not been proven in RCTs (10, 11).
While intervention in controlled trials were initiated relatively
late it would be challenging to achieve earlier treatment in routine
clinical practice.
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CRITERIA 2: IS THERE AN ACCEPTED
TREATMENT?
Pros
Levothyroxine is a safe and well-tolerated treatment
for hypothyroidism (7). There is extensive data on its
pharmacokinetics and over 50 years of experience with
the synthetic form of the drug (31). Other preparations
such as liothyronine and desiccated thyroid extract are
not recommended in pregnancy due to safety concerns
(16). In symptomatic patients with overt hypothyroidism
Levothyroxine leads to rapid improvement in well-being
and has been shown to improve pregnancy outcomes (26).
Inadequate levothyroxine correction may also lead to pregnancy
loss even in women established on treatment (32). The
thionamide compounds, Methimazole, its pro-drug derivative,
Carbimazole, and Propylthiouracil are the mainstay of treatment
for hyperthyroidism in pregnancy. While these compounds
are associated with a number of rare side effects, including
embryopathy and maternal liver failure (33), they are generally
safe and well-tolerated, with benefits that outweighs the risk of
fetal harm from drug side effects.
Cons
Although Levothyroxine is the accepted treatment for
overt hypothyroidism its benefits in gestational subclinical
thyroid dysfunction remains uncertain. More so, the use
of Levothyroxine is not without the risk of over-treatment
especially in women with borderline abnormalities. Studies have
shown a high proportion of over-treatment in levothyroxine
users ranging from 20 to 40% in the general population (31),
and 10% during pregnancy in the CATS study (10). Korevaar
et al. have shown an inverted U-shaped association between
maternal T4 and child IQ with IQ deficits of 1.4–3.8 points at the
extremes of T4 (34). Thus, inappropriate use of Levothyroxine
could potentially do more harm than good.
CRITERIA 3, 5, 6: ARE FACILITIES FOR
DIAGNOSIS AND TREATMENT READILY
AVAILABLE, IS THERE A SUITABLE TEST
OR EXAMINATION AND IS THE TEST
ACCEPTABLE TO THE POPULATION?
Pros
The diagnosis of thyroid dysfunction is established by
measurement of the thyroid hormones FT4, FT3, and TSH
(16). In addition, thyroid peroxidase antibodies (TPOAb) and
TSH receptor antibodies (TRAb) may be tested to confirm
autoimmunity which is the commonest cause of thyroid
dysfunction in iodine-replete countries. These simple non-
invasive tests are relatively inexpensive and available in modern
laboratories. Pharmacological treatments for thyroid dysfunction
are easily accessible and guidance for their use and monitoring
is well-established. In pregnancy, it is recommended that each
laboratory derive its own trimester specific reference range
using a local population of thyroid disease-free pregnant women
(16, 35). In the absence of local data, reference ranges may be
extrapolated from a population with similar ethnicity, iodine
nutrition, and assay methods (1, 16) or as suggested by the
current guidelines of the American Thyroid Association (ATA),
the TSH reference range in pregnancy may be set at 0.5 and
0.4 mU/L below the upper and lower non-pregnant limits,
respectively (16).
Cons
The assessment of thyroid function in pregnancy is by no
means straightforward and is subject to misinterpretation due
to the range of physiological adaptations that maintain fetal
thyroid hormone delivery in the face of increased thyroid
hormone requirements (36). These changes, including increased
thyroxine binding globulin production, stimulation of the TSH
receptor by hCG, and increased peripheral thyroid hormone
metabolism, all have implications for the evaluation of thyroid
function tests in pregnancy (37). Although gestation specific
reference ranges are recommended, many centers use the general
population reference ranges or continue to use the 2.5/3.0 mU/L
threshold which would lead to over-diagnosis. Furthermore, the
pregnancy-specific reference ranges in use are typically derived
from cross-sectional samples that do not account for differences
in longitudinal trajectories between healthy and autoimmune
thyroid disease states as demonstrated in recent studies (38, 39).
CRITERIA 4, 7: IS THERE A
RECOGNIZABLE LATENT OR EARLY
SYMPTOMATIC STAGE AND IS THE
NATURAL HISTORY OF THE CONDITION
UNDERSTOOD?
Pros
Subclinical hypothyroidism and thyroid autoimmunity may
represent early-disease states in the evolution of hypothyroidism.
Subclinical hypothyroidism is present in 4–10% of the general
population (40) and progresses to overt hypothyroidism at a
rate of about 2–5% per annum or higher in the presence
of antibodies (41). In pregnancy, about 25% of women with
subclinical hypothyroidism will have persistent TSH elevation
following delivery (42). Positive thyroid antibodies in euthyroid
women, i.e., euthyroid autoimmunity, is seen in about 10%
of pregnant women (43), a fifth of whom will develop
hypothyroidism in the course of pregnancy (44). The obstetric
consequences of euthyroid autoimmunity remain controversial
but an increased risk of pregnancy loss has been observed in
meta-analyses of spontaneous and assisted pregnancies (45, 46).
Possible mechanisms for such pregnancy loss include intrinsic
thyroid hormone deficiency, diffuse autoimmunity, and impaired
thyroidal response to hCG (3, 39, 47).
Cons
It can be difficult, without the appropriate expertise, to reliably
distinguish pathological thyroid disease from non-significant
fluctuations in thyroid hormones. Although subclinical disease
may precede overt disease, not all patients with subclinical
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disease develop overt disease. More importantly, the wealth
of observational data showing an increased risk of adverse
pregnancy outcomes in women with subclinical thyroid
dysfunction are not reconciled with data from randomized
controlled trials. Thus, targeting subclinical thyroid disease in
pregnancy will inadvertently promote overdiagnosis and fuel
unwarranted clinician and patient anxiety.
CRITERIA 8. IS THERE AN AGREED
POLICY ON WHOM TO TREAT?
Pros
All society guidelines endorse the treatment of overt thyroid
disease and in addition, most recommend treating antibody-
positive womenwith subclinical hypothyroidism (16, 48, 49). The
approach to euthyroid autoimmunity or women with subclinical
hypothyroidism and negative antibodies is less consistent (16,
50). As with other screening programmes shared treatment
decisions can be reached with patients following a fully informed
discussion of potential risks and benefits.
Cons
Navigating the various diagnostic gray areas could be challenging
for general clinicians and patients alike. An individualized
approach is reasonable but will be difficult to administer outside
of special-interest units. Ultimately, frontline clinicians may be
overwhelmed by demands for treatment from an increasingly
health-seeking population.
CRITERIA 9 AND 10. IS THE COST OF
CASE-FINDING (INCLUDING DIAGNOSIS
AND TREATMENT OF PATIENTS
DIAGNOSED) ECONOMICALLY VIABLE?
CASE-FINDING SHOULD BE A
CONTINUING PROCESS AND NOT A
“ONCE AND FOR ALL” PROJECT
Pros
Current international guidelines recommend screening for
thyroid dysfunction in women at high risk of thyroid
dysfunction, i.e., case-finding. However, various antenatal clinic
studies have consistently shown that case-finding fails to diagnose
30–80% of women with hypothyroidism (51–54). An economic
analysis using a state transition Markov model compared
the cost-effectiveness of universal screening, comprising first
trimester TSH and TPOAb measurements, case-finding, and no-
screening (55). Of the three strategies, universal screening was the
most cost-effective with an incremental cost-effectiveness ratio of
7258 USD per quality-adjusted life year (QALY) over risk-based
screening. Importantly, universal screening remained cost–
effective if the model assumed that only overt hypothyroidism
was associated with adverse obstetric outcomes with a cost-
effectiveness ratio of $7335/QALY over risk-based screening (55).
In another study from Spain the authors estimated that use of
universal screening over high-risk screening would yield annual
savings of e2,653,854 for the Spanish National Health System
with an incremental cost-effectiveness ratio of e374.28/QALY
over no screening (56). These figures compare favorably to
the cost-effectiveness of gestational diabetes mellitus screening
($12,078/QALY) in the United States for example (57) and is
well below the $50,000/QALY threshold for which a screening
intervention is considered value for money.
Cons
The analysis by Dosiou et al. was based on two RCTs conducted
in Southern Italy, an area of mild iodine deficiency. There is
no guarantee that the benefit reported in these studies will be
applicable to countries with different iodine nutrition or resource
settings. Furthermore, the overall costs of establishing a universal
screening programme will need to be carefully considered and
will need to incorporate the costs of personnel training, public
education, establishment of healthcare infrastructure, and the
burden of over-diagnosis and over-treatment.
DISCUSSION
In this appraisal, we have examined the pros and cons of universal
thyroid screening in early pregnancy using the template set
by Wilson and Jungner. Our analysis presents a number of
compelling arguments in support of universal screening but
also raises areas of uncertainties and practical caveats. Universal
thyroid screening in pregnancy fulfills most of the criteria for
screening (Table 1). Thyroid disease is an important health
problem in pregnancy with acceptable and well-established
treatments. Diagnostic facilities are available and relatively
inexpensive and there is adequate knowledge on the natural
history and impact of thyroid disorders on feto-maternal well-
being. Screening all pregnant women with TSH and TPOAb in
the first trimester of pregnancy is cost-effective compared to
targeted or no screening at all and benefits are apparent even
if only overt hypothyroidism was considered (55). Although the
merits of treating maternal subclinical thyroid dysfunction have
not been proven in RCTs it is probable that treatment in current
RCTs was started too late in pregnancy to be effective (10, 11).
Of all ten criteria, only criteria 8, “there should be an agreed
policy on whom to treat as patients,” is not satisfied. This is
understandable given that thyroid dysfunction, like some other
conditions with screening programmes such as hypertension
or dyslipidaemia, is a continuum in which the thresholds
for intervention are uncertain. Whilst all societal guidelines
endorse treatment of overt thyroid disease, the uncertainty
lies in the management of subclinical hypothyroidism, isolated
hypothyroxinemia, and euthyroid autoimmunity. Here, the
current ATA guidance (16) to definitely treat women with TSH
> 10 mU/L or antibody-positive women with TSH > 4.0 mU/L
seems logical as such women almost certainly have intrinsic
thyroid disease and will progress to thyroid failure. The less
prescriptive advice in gray areas provides flexibility for shared
clinician patient decisions in particular the fact that treatment
can be considered in TPO antibody positive women with a TSH
> 2.5 mU/l. More research is needed to understand the impact
of euthyroid autoimmunity or isolated hypothyroxinaemia. Of
interest will be the results of the TABLET trial, a large multicentre
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TABLE 1 | Appraisal of universal thyroid screening in pregnancy based on the Wilson and Jungnen criteria.
Criteria Hypothyroidism Hyperthyroidism Comments
1 Importance Common condition with established adverse feto-maternal effects
2 Accepted treatment Accepted for overt disease but uncertain for subclinical thyroid dysfunction
3 Facilities available Widely available and relatively inexpensive
4 Latent period May be difficult to distinguish physiological from subclinical states
5 Suitable test Need for local gestational age-specific reference ranges
6 Acceptable test Acceptable and established
7 Natural history May be difficult to distinguish physiological adaptations from true pathology
8 Agreed policy No consensus for subclinical thyroid dysfunction
9 Economically viable Cost-effective overall and for overt hypothyroidism only
10 Continuing Process Screening is a continuing process
, Fulfills criteria; , Partially fulfills criteria; , Does not fulfill criteria.
UK randomized controlled trial of Levothyroxine on pregnancy
and neonatal outcomes in women with thyroid antibodies (58).
A number of practical considerations will need to be
addressed before a universal thyroid screening can be safely
implemented. First, the use of pregnancy specific reference ranges
derived from a local population of thyroid disease-free pregnant
women should be considered a priority, even a prerequisite for
thyroid disease management in pregnancy. This will go some
way in distinguishing true pathology from pregnancy induced
physiological adaptation and will help curtail the dilemma
of over-diagnosis. Second is the need to establish consensus
criteria and unified nomenclature for the diagnosis of thyroid
conditions in pregnancy, using definitions that are adaptable
across populations and laboratories. The acquisition of skills
in interpreting abnormal thyroid function tests in pregnancy
by endocrinologists and obstetricians and the availability of
resource, referral pathways, and well-defined inter-disciplinary
responsibilities is essential.
The ultimate aim of maternal thyroid disease screening
in pregnancy is to optimize feto-maternal outcomes. Thus,
therapeutic intervention when indicated should be implemented
as early as possible in the course of fetal development.
Accordingly, universal screening should ideally be performed
once pregnancy is suspected or pre-conception if pregnancy
is planned. A pragmatic algorithm is to measure TSH and
then reflex FT4 and TPOAb if TSH is outside of the relevant
reference range. This will be challenging to achieve but with
thoughtful planning can be integrated into routine community
health services. An example of good practice in this regard
is China’s national free preconception health examination
project which offers access to preconception health examinations
including thyroid hormone measurement in rural parts of
China (14). A recent analysis of 184,611 pregnant participants
in this programme showed an association between higher
preconception TSH concentrations and risks of miscarriages
and pre-term loss, highlighting opportunities for modifying
pregnancy outcomes with preconception care (59).
Most national societies recommend targeted case-finding,
although with an expanding definition of high-risk (16). In
practice there is wide variation ranging from case-finding to
a near-universal or universal approach. For example, 42% of
European endocrinologists reported that they routinely screen
all women in pregnancy while 43% performed targeted high-risk
case finding (60). In contrast 85% of women in routine antenatal
clinics in Boston underwent screening (53). Several national
societies now recommend universal screening programmes. The
Polish Society of Endocrinology recommend measuring TSH
either preconception or at 4–8 weeks gestation in all pregnant
women (15). Likewise, the Spanish Society of Gynecology and
Obstetrics recommend universal screening with TSH levels in the
first 10 weeks of gestation and then FT4 if TSH > 2.5 mU/L (13).
Continuous audit, review and refinement of these programmes
will be essential for understanding the impact of screening.
Ensuring preconception iodine sufficiency through
targeted public health campaigns and sufficient prenatal
iodine supplementation should be integrated with thyroid
screening programmes. Iodine deficiency is common during
pregnancy, particularly in Europe (61) and correction of
mild-moderate iodine deficiency may have obstetric and
offspring benefits (62) although a recent large trial of iodine
supplementation in pregnancy in mild iodine deficiency failed to
show benefits on offspring IQ (63). However, in countries like the
United Kingdomwhich are iodine deficient in pregnancy with no
routine iodine fortification programs, iodine supplementation
during pregnancy and ideally 3 months prior to conception
is desirable (64). The United Kingdom position is surprising
given the action already taken by most other high, middle
and low income countries to have iodine fortification if they
are also iodine deficient in pregnancy Iodine supplementation
may also be of benefit to some high risk groups for pregnancy.
Certain population groups are at increased risk of being iodine
deficient. In particular, obese women are more likely to be
iodine deficient and have other micro-nutrient deficiencies in
pregnancy (65).
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CONCLUSION
Universal thyroid screening in pregnancy fulfills most criteria
for a beneficial and cost-effective screening programme and
holds promise for improving fetal and maternal outcomes.
However, areas of uncertainty remain especially with regards
to the significance of borderline biochemical abnormalities and
whether correction of such abnormalities can improve outcomes.
A consensus is unlikely to be reached without further controlled
trials and such trials should aspire to recruit women pre-
conception or as early as possible in pregnancy. In the interim
regular audit of existing screening programmes will be crucial
in gaining insights into the practicalities of universal thyroid
screening in pregnancy. For centers undertaking universal or
high-risk screening integrating thyroid auto-immunity into
decision making is essential.
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